Science & Enterprise subscription

Follow us on Twitter

  • A biotechnology company using protein dynamics to develop precision cancer therapies is acquiring a drug discovery… https://t.co/AzEb3ERy5f
    about 5 hours ago
  • New post on Science and Enterprise: AI Drug Discovery Company Acquired in $270M Deal https://t.co/GhPSuGMAHO #Science #Business
    about 5 hours ago
  • Drug maker Eli Lilly and Co. asked the Food and Drug Administration to revoke its authorization for bamlanivimab al… https://t.co/xtrdcKMDgx
    about 11 hours ago
  • New post on Science and Enterprise: Lilly Asks FDA to Revoke Covid-19 Therapy Clearance https://t.co/FNA6Qlklwy #Science #Business
    about 11 hours ago
  • Vaccine developer Novavax is taking part in a clinical trial testing effects of different Covid-19 vaccines in firs… https://t.co/AMeVYLYh30
    about 1 day ago

Please share Science & Enterprise

Infographic – Covax Begins Vaccine Deliveries

Chart: Covax deliveries

Click on image for full-size view (Statista)

27 Mar. 2021. The Covid-19 Vaccine Global Access, or Covax facility, backed by World Health Organization, European Union, and non-government organizations, started up last year to provide worldwide equitable access to Covid-19 vaccines. Data from Unicef displayed this week in a chart by the business research group Statista, shows since late February Covax began delivering vaccines to some low- and middle-resource countries.

Covax is distributing the Oxford/AstraZeneca Covid-19 vaccine, made under contract by the Serum Institute in India and SK Bioscience in South Korea. So far, Serum Institute began filling allotments in Nigeria, Ethiopia, and Democratic Republic of the Congo, while SK Bioscience made smaller deliveries to Indonesia, Brazil, and the Philippines. Deliveries so far represent a small fraction of the allotments to those countries, with deliveries for other allotments not yet underway.

Future deliveries from the Serum Institute were clouded by India’s announcement this week that it would delay exports of Covid-19 vaccines, including those to Covax, until its domestic needs were filled. The U.S. could step in later this Spring, since it may have a surplus of vaccines by May, according to the New York Times. As reported by Science & Enterprise, the U.S. rejoined World Health Organization soon after Joe Biden took office, with Congress earlier appropriating $3.36 billion for the Covax project.

More from Science & Enterprise:

*     *     *

Comments are closed.